Neil Stahl - Regeneron Pharmaceuticals Insider

Regeneron Pharmaceuticals Inc -- USA Stock  

USD 433.82  0.84  0.19%

Executive VP of RandD

Dr. Neil Stahl, Ph.D., is Executive Vice President Research and Development Sciences of the Company. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction
Age: 59  EVP Since 2014  Ph.D    
914 847-7000  www.regeneron.com
Stahl received his Ph.D. in Biochemistry from Brandeis University.

Neil Stahl Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 14.77 % which means that it generated profit of $14.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.06 % meaning that it created $24.06 on every $100 dollars invested by stockholders.
The company currently holds 701.17 M in liabilities with Debt to Equity (D/E) ratio of 12.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals Inc has Current Ratio of 3.68 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

EVP Since

John CapekAbbott Laboratories
2015
Hubert AllenAbbott Laboratories
2013
Thomas FreymanAbbott Laboratories
2015
Brian BlaserAbbott Laboratories
2012
Susan HallEndo International plc
2014
Giovanni MagniBio Rad Laboratories Inc
2014
Richard AshleyAbbott Laboratories
2004
Stuart ArbuckleVertex Pharmaceuticals Incorpor
2012

Entity Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals Inc (REGN) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 4,786 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Diagnostics Now
   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
Hide  View All  Next  Launch Portfolio Diagnostics
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Regeneron Pharmaceuticals Inc to your portfolio

Top Management

Regeneron Pharmaceuticals Leadership Team
Charles Baker, Director
Robert Ingram, Director
Joseph Goldstein, Director, Ph.D
Anthony Coles, Director
George Sing, Director
Peter Powchik, President
Jay Markowitz, President
Robert Terifay, SVP
Robert Landry, CFO
Michael Brown, Director, Ph.D
Christine Poon, Director
Neil Stahl, EVP, Ph.D
George Yancopoulos, President
Huda Zoghbi, Director, Ph.D
Bonnie Bassler, Director
Joseph LaRosa, President
Daniel Plew, President, MBA
Leonard Schleifer, CEO, Ph.D
Alfred Gilman, Director, Ph.D
Roy Vagelos, Chairman, Ph.D
Michael Aberman, President, MBA
Manisha Narasimhan, Executive
Douglas McCorkle, President
P Vagelos, Chairman, Ph.D
Marc TessierLavigne, Director, Ph.D
Christopher Fenimore, President, MBA
Arthur Ryan, Director

Stock Performance

Regeneron Pharmaceuticals Performance Indicators